🎉 Big congratulations to our alumni CUTISS AG with CEO Daniela Marino! They’ve just closed a CHF 56M Series C round, bringing their total funds raised to over CHF 125M. 🚀 🌟✨ With this milestone, CUTISS is moving closer to commercializing denovoSkin™ and scaling up production through their automated platform — plus expanding into the Netherlands with a new center of excellence. 👏 We are inspired by Daniela Marino and her team’s resilience, vision, and dedication. CUTISS is paving the way for groundbreaking innovation in regenerative medicine, and we’re honored to have supported them in their early journey. #AlumniSuccess #Innovation #Scaleup #LifeSciences
#𝐁𝐑𝐄𝐀𝐊𝐈𝐍𝐆𝐍𝐄𝐖𝐒 𝐟𝐨𝐫 𝐂𝐔𝐓𝐈𝐒𝐒 We’ve successfully closed our Series C financing round at CHF 56 million and signed a strategic agreement with the Rode Kruis Ziekenhuis, paving the ground for a future CUTISS center of excellence in the Netherlands. This new round brings our total funds raised to date to over CHF 125 million, and will primarily support: 🔹 Our 𝐏𝐡𝐚𝐬𝐞 𝟯 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥 of denovoSkin™ towards 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻, and 🔹 The 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝗶𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻 of our proprietary 𝗮𝘂𝘁𝗼𝗺𝗮𝘁𝗲𝗱 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝗳𝗼𝗿 𝘀𝗰𝗮𝗹𝗶𝗻𝗴 𝘂𝗽 tissue therapy production The Brandwondencentrum Beverwijk at RKZ is a leading European burn center, and we truly look forward to deepening our collaboration to make sure that denovoSkin™ will soon reach many patients in need. 💬 “Closing this round has been a journey of resilience, commitment, strategic moves, and of course a pinch of luck. We’re proud to have come this far, with commercialization now visible on the not-so-distant horizon,” says Daniela Marino, CEO and co-founder. “We work hard to earn the trust of our stakeholders by delivering results – and it has paid off.” A big thank you to our existing and new investors, collaborators, partners, surgeons and study teams, patients and supporters! BIG KUDOS to the whole team at CUTISS: let’s #gogogo ! 🚀 Tecan Swisspreneur Greater Zurich Area
